Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

erdafitinib
measurable disease
dose regimen
adjuvant chemotherapy
renal function
  • 40 views
  • 29 May, 2021
  • 151 locations
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor

growth factor
erdafitinib
advanced urothelial carcinoma
adjuvant chemotherapy
vinflunine
  • 271 views
  • 03 Jun, 2021
  • 588 locations
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab

growth factor
solid tumour
measurable disease
advanced urothelial carcinoma
metastasis
  • 95 views
  • 02 Jun, 2021
  • 198 locations
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in participants with advanced solid tumors with fibroblast growth factor receptor

growth factor
solid tumour
cancer
measurable disease
  • 33 views
  • 31 May, 2021
  • 264 locations
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive

growth factor
human chorionic gonadotropin
bcg vaccine
bladder tumor
gemcitabine
  • 0 views
  • 30 May, 2021
  • 188 locations
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the

testosterone
measurable disease
tumor cells
testosterone level
adenocarcinoma
  • 0 views
  • 13 Jun, 2021
  • 1 location
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in

MRI
antibody therapy
stem cell infusion
iobenguane
metastasis
  • 261 views
  • 13 Jun, 2021
  • 81 locations
  • 12 views
  • 05 Feb, 2021
  • 3 locations
FGFR Inhibitor in FGFR Dysregulated Cancer

erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease progression or unacceptable

growth factor
solid tumour
erdafitinib
cancer chemotherapy
FGFR1
  • 4 views
  • 26 Jan, 2021
  • 13 locations